• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

    6/5/25 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email

    - DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model -

    WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) --  Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it will be presenting new preclinical data demonstrating the potential of DYNE-302 to achieve functional improvement in facioscapulohumeral muscular dystrophy (FSHD). The data will be presented at the 32nd Annual FSHD Society's International Research Congress being held June 12-13, 2025, in Amsterdam.

    In a mouse model of severe FSHD, a single intravenous dose of DYNE-302 administered at the peak of muscle weakness restored ability to run on a treadmill. Analysis of gene activity in skeletal muscle indicated correction of muscle damage and inflammation. These findings suggest that preexisting and severe skeletal muscle disease in FSHD has the potential to be reversed by targeting the DUX4 mRNA with DYNE-302. 

    FSHD is a rare, progressive, inherited muscle disease. De-repression of DUX4 in skeletal muscle drives disease pathogenesis, leading to muscle damage and loss of function. This results in a range of symptoms that restrict daily activities and have a high physical, emotional, and financial burden. DYNE-302 leverages a TfR1-targeting Fab for muscle delivery of an siRNA payload highly specific for DUX4 mRNA with the aim of suppressing DUX4 expression and the downstream DUX4 transcriptome.

    Oral Presentation: DYNE-302 leads to functional improvement and resolves muscle transcriptomic changes in mouse models of FSHD

    Session: Mechanisms of Disease & Interventional Strategies

    Date/Time: Friday, June 13, 2025, at 12:00 p.m. CEST / 6:00 a.m. ET.

    Presenter: Stefano Zanotti, PhD, Head of Neuromuscular Research, Dyne

    The presentation will also be available in the Scientific Publications & Presentations section of Dyne's website following the session.

    About Facioscapulohumeral Muscular Dystrophy (FSHD)

    FSHD is a rare, progressive, genetic disease caused by a mutation in the DUX4 gene, leading to skeletal muscle loss, muscle weakness and wasting. Individuals with FSHD carry a genetic mutation that allows the DUX4 gene to be sporadically activated in muscle cells, causing their gradual destruction throughout the body. People living with FSHD experience weakness in all major muscle groups throughout the body and limited mobility. An estimated 16,000 to 38,000 individuals in the United States and approximately 35,000 in Europe are affected by FSHD, but there are currently no approved therapies.

    About Dyne Therapeutics

    Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit and follow us on X, LinkedIn and Facebook.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the potential of DYNE-302, and the sufficiency of Dyne's cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and as to the regulatory approval process for Dyne's product candidates; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the company's most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release.

    Contacts:

    Investors

    Mia Tobias

    [email protected]

    781-317-0353  

    Media

    Stacy Nartker

    [email protected]

    781-317-1938



    Primary Logo

    Get the next $DYN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    3/12/2025$50.00Outperform
    BMO Capital Markets
    3/7/2025$50.00Sector Outperform
    Scotiabank
    12/13/2024$46.00Outperform
    Robert W. Baird
    11/26/2024$45.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Friedl-Naderer Johanna

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      7/18/25 5:21:09 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Kerr Douglas

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      7/18/25 5:20:39 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO & President Cox John

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      7/18/25 5:19:53 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bernstein initiated coverage on Dyne Therapeutics with a new price target

      Bernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00

      6/24/25 8:00:58 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Dyne Therapeutics with a new price target

      Raymond James resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $37.00

      6/11/25 7:53:49 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Dyne Therapeutics with a new price target

      Oppenheimer resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $34.00

      6/2/25 8:51:54 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

      Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p

      7/16/25 7:00:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

      WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced underwritten public offering of 27,878,788 shares of its common stock at a public offering price of $8.25 per share, which includes 3,636,363 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $230.0 million, before deducting underwriting discounts and commissions a

      7/2/25 4:01:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

      WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditi

      6/30/25 9:45:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Cox John gifted 40,000 shares and bought $911,000 worth of shares (100,000 units at $9.11), increasing direct ownership by 42% to 202,179 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      7/15/25 5:11:40 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & President Cox John bought $1,057,216 worth of shares (32,000 units at $33.04) (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      9/4/24 5:42:18 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kersten Dirk bought $29,999,988 worth of shares (1,714,285 units at $17.50) (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      1/11/24 4:31:55 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    SEC Filings

    See more
    • SEC Form 424B5 filed by Dyne Therapeutics Inc.

      424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

      7/1/25 4:49:58 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Dyne Therapeutics Inc.

      8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

      7/1/25 4:40:23 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Dyne Therapeutics Inc.

      424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

      6/30/25 4:43:07 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Leadership Updates

    Live Leadership Updates

    See more
    • Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

      Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p

      7/16/25 7:00:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces CEO Transition

      - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamles

      3/25/24 7:30:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development

      - Appointment Expands Dyne's Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Francesco Bibbiani, M.D., as senior vice president, head of development. Dr. Bibbiani brings more than two decades of experience across development, including a focus on rare neuromuscular diseases as well as Duchenne muscular dystrophy (DMD). "We are excited to welcome Francesco to Dyne's development

      8/29/22 7:30:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

      SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

      11/14/24 5:46:12 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

      SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

      11/14/24 4:32:40 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

      SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

      11/14/24 4:23:11 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Financials

    Live finance-specific insights

    See more
    • Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

      - Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically

      6/17/25 7:00:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

      WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days followin

      6/16/25 4:05:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

      - DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential to support H1 2026 submission for U.S. Accelerated Approval - - DYNE-251 in Exon 51 DMD: Based on recent FDA feedback, pursuing U.S. Accelerated Approval with dystrophin as surrogate endpoint; data from ongoing Registrational Expansion Cohort in DELIVER trial expected late 2025 with potential to support early 2026 regulatory submission - - Investor event today, January 10th at 8:00 a.m. ET - WALTHAM, Mass., Jan. 10, 2025 (GLOBE NE

      1/10/25 6:30:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care